Compare XPER & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPER | ACRS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | 1460 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.7M | 311.0M |
| IPO Year | 2021 | 2015 |
| Metric | XPER | ACRS |
|---|---|---|
| Price | $5.48 | $3.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.00 | $9.75 |
| AVG Volume (30 Days) | 367.9K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $448,105,000.00 | $1,683,000.00 |
| Revenue This Year | $4.03 | N/A |
| Revenue Next Year | $8.11 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.07 | $1.05 |
| 52 Week High | $8.24 | $4.89 |
| Indicator | XPER | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 51.44 |
| Support Level | $5.07 | $2.67 |
| Resistance Level | $6.37 | $3.86 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 4.41 | 42.57 |
Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.